"Analysis.group","Analysis.number","Analysis.name","Subgroup","Subgroup.number","Applicability","Study","Study.year","GIV.Mean","GIV.SE","Experimental.mean","Experimental.SD","Experimental.cases","Experimental.N","Control.mean","Control.SD","Control.cases","Control.N","O.E","Variance","Weight","Mean","CI.start","CI.end","Footnotes","Bias.arising.from.the.randomization.process.judgement","Bias.arising.from.the.randomization.process.support","Bias.due.to.deviations.from.intended.interventions.judgement","Bias.due.to.deviations.from.intended.interventions.support","Bias.due.to.missing.outcome.data.judgement","Bias.due.to.missing.outcome.data.support","Bias.in.measurement.of.the.outcome.judgement","Bias.in.measurement.of.the.outcome.support","Bias.in.selection.of.the.reported.result.judgement","Bias.in.selection.of.the.reported.result.support","Overall.bias.judgement","Overall.bias.support","review.url","review.doi","analysis_key","dataset_name","mismatch_type","direction_match","or_sig","rd_sig","log_or","rd","log_or_ci_lb","log_or_ci_ub","rd_ci_lb","rd_ci_ub","sparse_events","double_zero"
1,14,"Analysis 1.14. Outcome 6: Proportion of participants without improvement of steatosis: sensitivity analysis fixed-effect model",NA,NA,"SUBGROUP_AND_OVERALL","Chan 2017",2017,0,0,0,0,40,49,0,0,37,50,0,0,55.053166,1.103144,0.89306,1.362649,NA,"Low risk","<p><b>Quote:</b> “a computer-generated table of random numbers was utilized with a simple randomization method; the numbers were kept centrally at this institution’s Clinical Investigation Center and released to a research assistant only after a subject was recruited into the study; the baseline characteristics were comparable between the groups...”</p>","Low risk","<p><b>Quote:</b> “clinical investigators were not aware of the treatment group assignment as they were packaged in a similar manner; analyses were based on intention to treat unless stated otherwise”</p>","Low risk","<p><b>Quote:</b> “analyses were based on intention to treat unless stated otherwise”</p>","Low risk","<p><b>Quote: </b>“histopathological findings were reported according to the Nonalcoholic Steatohepatitis Clinical Research Network Scoring System; liver biopsy slides were examined by an experienced histopathologist (N.R.N.M.) who was blinded to the clinical data”</p>","Low risk","<p><b>Quote: </b>“according to the online registration information, the data that produced this result analysed in accordance with a pre-specified analysis plan; ...were obtained using a standard protocol at baseline and at Weeks 12, 24, 36, and 48”</p>","Low risk","<p>All domains were judged to be 'low' risk of bias</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015524.pub2/full","10.1002/14651858.CD015524.pub2","14::overall","CD015524_pub2_data","direction_only",FALSE,FALSE,FALSE,0.137845996894391,-0.0160072821975777,-0.584993903982129,0.86068589777091,-0.154967808032698,0.122953243637543,TRUE,TRUE
1,14,"Analysis 1.14. Outcome 6: Proportion of participants without improvement of steatosis: sensitivity analysis fixed-effect model",NA,NA,"SUBGROUP_AND_OVERALL","Navarro 2019",2019,0,0.25575479547902,0,0,20,26,0,0,11,12,0,0.0654105154105154,22.625705,0.839161,0.639975,1.100341,NA,"Low risk","<p><b>Quote:</b> “participants were allocated...by means of a web-based system; participants were randomly assigned by the Data Coordinating Center at the University of PIttsburgh to 1 of 3 treatment groups; the baseline demographic, clinical, laboratory... characteristics of the three treatment groups were similar in the ITT population”</p>","Low risk","<p><b>Quote: </b>“participants, investigators, clinical site staff and pathologists were masked to treatment assignment; statistical analyses for the primary efficacy assessments were carried out on the Intention-To-Treat (ITT) population”</p>","Low risk","<p><b>Quote: </b>“statistical analyses for the primary efficacy assessments were carried out on the Intention-To-Treat (ITT) population”</p>","Low risk","<p><b>Quote: </b>“biopsies were scored by site pathologists according to the Nonalcoholic Steatohepatitis Clinical Research Network proposal for...; participants, investigators, clinical site staff and pathologists were masked to treatment assignment”</p>","Low risk","<p><b>Comment: </b>according to the online registration information, the data that produced this result analysed in accordance with a pre-specified analysis plan; according to the results, outcome measured and analysed at baseline and after 48-50 weeks of treatment</p>","Low risk","<p>All domains were judged to be 'low' risk of bias</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015524.pub2/full","10.1002/14651858.CD015524.pub2","14::overall","CD015524_pub2_data","direction_only",FALSE,FALSE,FALSE,0.137845996894391,-0.0160072821975777,-0.584993903982129,0.86068589777091,-0.154967808032698,0.122953243637543,TRUE,TRUE
1,14,"Analysis 1.14. Outcome 6: Proportion of participants without improvement of steatosis: sensitivity analysis fixed-effect model",NA,NA,"SUBGROUP_AND_OVERALL","Navarro 2019",2019,0,0.149678062532632,0,0,22,27,0,0,11,13,0,0.0224035224035223,22.321129,0.962963,0.718131,1.291266,NA,"Low risk","<p><b>Quote:</b> “participants were allocated...by means of a web-based system; participants were randomly assigned by the Data Coordinating Center at the University of PIttsburgh to 1 of 3 treatment groups; the baseline demographic, clinical, laboratory... characteristics of the three treatment groups were similar in the ITT population”</p>","Low risk","<p><b>Quote: </b>“participants, investigators, clinical site staff and pathologists were masked to treatment assignment; statistical analyses for the primary efficacy assessments were carried out on the Intention-To-Treat (ITT) population”</p>","Low risk","<p><b>Quote: </b>“statistical analyses for the primary efficacy assessments were carried out on the Intention-To-Treat (ITT) population”</p>","Low risk","<p><b>Quote: </b>“biopsies were scored by site pathologists according to the Nonalcoholic Steatohepatitis Clinical Research Network proposal for...; participants, investigators, clinical site staff and pathologists were masked to treatment assignment”</p>","Low risk","<p><b>Comment: </b>according to the online registration information, the data that produced this result analysed in accordance with a pre-specified analysis plan; according to the results, outcome measured and analysed at baseline and after 48-50 weeks of treatment</p>","Low risk","<p>All domains were judged to be 'low' risk of bias</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015524.pub2/full","10.1002/14651858.CD015524.pub2","14::overall","CD015524_pub2_data","direction_only",FALSE,FALSE,FALSE,0.137845996894391,-0.0160072821975777,-0.584993903982129,0.86068589777091,-0.154967808032698,0.122953243637543,TRUE,TRUE
2,14,"Analysis 2.14. Outcome 10: FBS (mmol/L) ",NA,NA,"SUBGROUP_AND_OVERALL","Hajiaghamohammadi 2012",2012,0,0.092072106130319,5.22,0.32,0,11,4.72,0.29,0,22,0,0.0084772727272727,50,0.5,0.2754,0.7246,NA,"Some concerns","<p><b>Quote:</b> “...randomly allocated patients into three intervention groups using 22 blocks A, B, C (ABC, ACB, etc.) of Balanced Blocked Randomization method”</p>
<p><b>Comment: </b>no information was given about the method of allocation sequence; no information was given about the baseline differences between intervention groups</p>","Low risk","<p><b>Comment: </b>according to the online registration information, the trial was double-blinded; analysis was based on intention-to-treat</p>","Low risk","<p><b>Quote:</b> “sixty-six subjects completed the study (22 in each study group); none of patients withdraw from study during research”</p>","Low risk","<p><b>Quote:</b> “other biochemical elements were assayed PARS-AZMOON manufactured DIASYS Germany Company”</p>
<p><b>Comment:</b> according to the online registration information, the trial was double-blind</p>","Low risk","<p><b>Quote:</b> “...were measured by laboratory kits; ...were measured in three groups before and after drug administration”</p>
<p><b>Comment:</b> according to the online registration information, the data that produced this result analysed were in accordance with a pre-specified analysis plan</p>","Some concerns","<p>One domain was judged to raise 'some concerns'</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015524.pub2/full","10.1002/14651858.CD015524.pub2","14::overall","CD015524_pub2_data","direction_only",FALSE,FALSE,FALSE,0.137845996894391,-0.0160072821975777,-0.584993903982129,0.86068589777091,-0.154967808032698,0.122953243637543,TRUE,TRUE
2,14,"Analysis 2.14. Outcome 10: FBS (mmol/L) ",NA,NA,"SUBGROUP_AND_OVERALL","Hajiaghamohammadi 2012",2012,0,0.114594145495388,5.22,0.32,0,11,4.86,0.29,0,22,0,0.0131318181818181,50,0.36,0.1354,0.5846,NA,"Some concerns","<p><b>Quote:</b> “...randomly allocated patients into three intervention groups using 22 blocks A, B, C (ABC, ACB, etc.) of Balanced Blocked Randomization method”</p>
<p><b>Comment: </b>no information was given about the method of allocation sequence; no information was given about the baseline differences between intervention groups</p>","Low risk","<p><b>Comment: </b>according to the online registration information, the trial was double-blinded; analysis was based on intention-to-treat</p>","Low risk","<p><b>Quote:</b> “sixty-six subjects completed the study (22 in each study group); none of patients withdraw from study during research”</p>","Low risk","<p><b>Quote:</b> “other biochemical elements were assayed PARS-AZMOON manufactured DIASYS Germany Company”</p>
<p><b>Comment:</b> according to the online registration information, the trial was double-blind</p>","Low risk","<p><b>Quote:</b> “...were measured by laboratory kits; ...were measured in three groups before and after drug administration”</p>
<p><b>Comment:</b> according to the online registration information, the data that produced this result analysed were in accordance with a pre-specified analysis plan</p>","Some concerns","<p>One domain was judged to raise 'some concerns'</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015524.pub2/full","10.1002/14651858.CD015524.pub2","14::overall","CD015524_pub2_data","direction_only",FALSE,FALSE,FALSE,0.137845996894391,-0.0160072821975777,-0.584993903982129,0.86068589777091,-0.154967808032698,0.122953243637543,TRUE,TRUE
3,14,"Analysis 3.14. Outcome 9: TC (mmol/L)",NA,NA,"SUBGROUP_AND_OVERALL","Ataee 2021",2021,0,0,4.54,1.11,0,30,4.64,0.86,0,30,0,0,32.802545,-0.1,-0.602467,0.402467,NA,"Some concerns","<p><b>Quote:</b> ""patients were devided to two groups by simple randomization through random number table that produced from PASS software; all baseline characteristics, including demographics...were similar between the two groups""</p><p><b>Comment:</b> no information was given about the method of allocation sequence</p>","Low risk","<p><b>Quote: </b>""...were entered into this randomized, triple-blind, placebo-controlled trial and assigned to two groups; similar capsules containing the formulation excipients were...; data were analyzed in consistent with the intention-to-treat approach""""</p>","Low risk","<p><b>Comment: </b>data were available for all participants randomized</p>","Low risk","<p><b>Quote:</b> ""...were entered into this randomized, triple-blind, placebo-controlled trial and assigned to two groups""</p><p><b>Comment:</b> according to the online registration information, TC was measured by autoanalyzer bt3000</p>","Low risk","<p><b>Quote: </b>""we measured laboratory tests once before the interventions and afterwards at the end of triple therapy (three months later)""</p><p><b>Comment:</b> according to the online registration information, the data that produced this result analysed in accordance with a pre-specified analysis plan</p>","Some concerns","<p> One domain was judged to raise 'some concerns'</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015524.pub2/full","10.1002/14651858.CD015524.pub2","14::overall","CD015524_pub2_data","direction_only",FALSE,FALSE,FALSE,0.137845996894391,-0.0160072821975777,-0.584993903982129,0.86068589777091,-0.154967808032698,0.122953243637543,TRUE,TRUE
3,14,"Analysis 3.14. Outcome 9: TC (mmol/L)",NA,NA,"SUBGROUP_AND_OVERALL","Li 2024",2024,0,0.179117142729757,5.29,0.96,0,60,5.3,1.01,0,61,0,0.0320829508196721,67.197455,-0.01,-0.361063,0.341063,NA,"Low risk","<p><b>Quote: </b>""...used gender-stratified block randomisation with 62 serial numbers per gender and block sizes of 4 and 6 in a random order; the entire intervention allocation remained blinded to all participants, care providers, clinical investigators, and statisticians until the data analysis was completed; at baseline, the sociodemographic characteristics...and medical history information were comparable between the two groups""</p>","Low risk","<p><b>Quote: </b>""this study was a triple-blind, randomized, placebo-controlled clinical trial...; the entire intervention allocation remained blinded to all participants, care providers, clinical investigators, and statisticians until the data analysis was completed; the analyses employed an intention-to-treat (ITT) approach""</p>","Low risk","<p><b>Quote: </b>""the analyses employed an intention-to-treat (ITT) approach""</p><p><b>Comment: </b>57 participants in the placebo group and 55 participants in the treatment group completed the study, respectively</p>","Low risk","<p><b>Quote: </b>""TC...and creatinine were conducted using corresponding commercial kits (Roche Diagnostics GmbH, Mannheim, Germany) by a Hitachi 7600-010 automated analyser (Hitachi, Tokyo, Japan); after overnight fasting, blood samples were collected by a trained nurse and serum were separated within 2 h and stored at 80 ℃ for subsequent analysis; this study was a triple-blind, randomised, placebo-controlled clinical trial...""</p>","Low risk","<p><b>Quote:</b> ""lipid levels, glucose metabolism...and alcohol metabolism of NAFLD patients at baseline and after 24 weeks of SPS intervention""</p><p><b>Comment:</b> according to the online registration information, the data that produced this result analysed in accordance with a pre-specified analysis plan</p>","Low risk","<p>All domains were judged to be 'low' risk of bias</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015524.pub2/full","10.1002/14651858.CD015524.pub2","14::overall","CD015524_pub2_data","direction_only",FALSE,FALSE,FALSE,0.137845996894391,-0.0160072821975777,-0.584993903982129,0.86068589777091,-0.154967808032698,0.122953243637543,TRUE,TRUE
4,14," Analysis 4.14. Outcome 11: HOMA-IR",NA,NA,"SUBGROUP_AND_OVERALL","Cerletti 2020",2020,0,0,4.23,3.46,0,62,4.33,2.74,0,64,0,0,100,-0.1,-1.19196,0.99196,NA,"Low risk","<p><b>Quote:</b> “the random allocation sequence to treatment was computer based per blocks of four or six subjects stratified for each recruiting centre; it was generated by the principal investigator (PI)’s statistician and forwarded to each recruitment centre; no differences were observed in the baseline levels of the hepatic enzymes...between the two treatment groups”</p>","Low risk","<p><b>Quote:</b> “participants, doctors, technicians and statisticians who participated or evaluated the study outcomes were blinded to the supplements; data were analysed according to the intention-to-treat approach”</p>","Low risk","<p><b>Quote:</b> “data were analysed according to the intention-to-treat approach”</p>","Low risk","<p><b>Quote: </b>“biochemical...were performed in the Neuromed Laboratory using standard photometric methods; participants, doctors, technicians and statisticians who participated or evaluated the study outcomes were blinded to the supplements”</p>","Low risk","<p><b>Quote:</b> “hepatic enzymes...were measured at baseline and after the 3-month”</p>
<p><b>Comment:</b> according to the online registration information, the data that produced this result analysed in accordance with a pre-specified analysis plan</p>","Low risk","<p>All domains were judged to be 'low' risk of bias</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015524.pub2/full","10.1002/14651858.CD015524.pub2","14::overall","CD015524_pub2_data","direction_only",FALSE,FALSE,FALSE,0.137845996894391,-0.0160072821975777,-0.584993903982129,0.86068589777091,-0.154967808032698,0.122953243637543,TRUE,TRUE
